tag enhertu 
pharmaphorum
APRIL 27, 2022
AstraZeneca and Daiichi Sankyo have claimed a fifth breakthrough designation from the FDA for Enhertu, shortly after showing the drug extended survival in patients with HER2-low metastatic breast cancer. The post Enhertu gets breakthrough tag in HER2-low breast cancer appeared first on.
pharmaphorum
DECEMBER 23, 2021
AZ has already licensed rights to HER2-targeting drug Enhertu (trastuzumab deruxtecan) – which is already on the market for HER2-positive breast and gastric cancers – as well as investigational TROP2 ADC datopotamab deruxtecan in two multibillion-dollar deals. Daiichi Sankyo and AZ are close collaborators in the ADC arena.
Expert insights. Personalized for you.
58 
Let's personalize your content